Euclid Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Euclid Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-146,799	Closed	-$7.37M	–	409
2016 Q2	$7.37M	Sell	146,799 -22,533	-13%	-$1.2M	0.32%	111
2016 Q1	$9.06M	Buy	169,332 +4,001	+2%	+$235K	0.34%	106
2015 Q4	$10.9M	Buy	165,331 +99,286	+150%	+$6.14M	0.33%	97
2015 Q3	$3.73M	Buy	+66,045	New	+$4.28M	0.17%	142
2015 Q2	–	Sell	-60,260	Closed	-$3.75M	–	512
2015 Q1	$3.75M	Buy	+60,260	New	+$3.5M	0.07%	231

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Euclid Advisors's TEVA Position: Q3 2016 in Review

Euclid Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2016, closing a stake of 146,799 shares — an estimated $7.37M sold.

Euclid Advisors first reported a position in TEVA in Q1 2015 and held it in 5 quarters. The position peaked at $10.9M in Q4 2015. 797 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

Euclid Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Euclid Advisors sold 146,799 Teva Pharmaceuticals shares in Q3 2016, an estimated $7.37M.
Euclid Advisors first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 5 quarters.
Euclid Advisors's Teva Pharmaceuticals position peaked at $10.9M in Q4 2015.
797 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2016.

Based on Euclid Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.